Literature DB >> 24088106

Eculizumab in atypical hemolytic-uremic syndrome.

Troels Ring.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24088106     DOI： 10.1056/NEJMc1308826

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.

Authors:  Maurizio Salvadori; Giuseppina Rosso; Elisabetta Bertoni
Journal:  World J Nephrol       Date:  2015-05-06

2.  Atypical hemolytic uremic syndrome: a clinical conundrum.

Authors:  Prabesh Bajracharya; Amrish Jain; Rossana Baracco; Tej K Mattoo; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2016-05-02       Impact factor: 3.714

3.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Authors:  Marina Noris; Miriam Galbusera; Sara Gastoldi; Paolo Macor; Federica Banterla; Elena Bresin; Claudio Tripodo; Serena Bettoni; Roberta Donadelli; Elisabetta Valoti; Francesco Tedesco; Alessandro Amore; Rosanna Coppo; Piero Ruggenenti; Eliana Gotti; Giuseppe Remuzzi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

4.  Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy.

Authors:  Meera Sridharan; Ronald S Go; Maria A V Willrich
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2022-09-17

5.  Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

Authors:  Philippe Gatault; Guillaume Brachet; David Ternant; Danielle Degenne; Guillaume Récipon; Christelle Barbet; Emmanuel Gyan; Valérie Gouilleux-Gruart; Cécile Bordes; Alexandra Farrell; Jean Michel Halimi; Hervé Watier
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.